Close
Novotech
Jabsco PureFlo 21 Single Use

News

Trump Announces 100% US Pharma Tariffs for Patented Drugs

The US pharma tariffs policy has been formalised through an executive order signed by Donald Trump, introducing tariffs of up to 100% on imported branded medicines. The measure targets pharmaceutical companies that have not entered into drug pricing agreements...

Biomaterials and Local Drug Delivery in Implant Surgery

Advances in biomaterials and localized drug delivery systems are transforming implant surgery across both medical and dental disciplines. Traditionally, implant success relied primarily on mechanical stability and surgical technique. Today, innovations in bioactive materials, surface engineering, and controlled drug delivery...

UK-US Pharma Trade Deal Drives Tariff Cuts, Pricing Shift

Britain has finalised a UK-US pharma trade deal, securing tariff-free access for UK-made medicines to the United States while committing to higher domestic spending and pricing adjustments for new drugs. The agreement, part of a broader bilateral trade framework...

Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal

Eli Lilly & Co. is set to acquire Centessa Pharmaceuticals Plc in a transaction worth up to $7.8 billion, underscoring its push to broaden its drug development pipeline. The Centessa Pharmaceuticals deal highlights the company’s effort to expand into therapeutic...

D2 Solutions Highlights Medication Access Delays in U.S.

New findings from healthcare consulting and technology company D2 Solutions indicate that medication access delays are influencing whether patients initiate prescribed therapies, with confusion and administrative hurdles emerging as key barriers. Based on a survey of 1,000 U.S. adults...

Johnson & Johnson Wins DARZALEX Self-Administration EU Nod

Johnson & Johnson has received a key regulatory endorsement in Europe, marking a significant shift in how oncology treatments can be administered. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has approved a...

Transcend Acquisition Advances Otsuka Neuroplastogen Focus

Japanese pharmaceutical company Otsuka has moved to deepen its presence in the emerging neuroplastogen space through an agreement to acquire Transcend Therapeutics, bringing with it a promising MDMA-based candidate targeting post-traumatic stress disorder (PTSD) and related psychiatric conditions. The...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »